Core Viewpoint - The report provides a detailed analysis of Shanghai Haili Biotechnology Co., Ltd.'s financial performance, highlighting significant revenue growth and profit fluctuations, as well as the impact of asset restructuring on the company's operational capabilities [1][10]. Financial Performance - In 2024, the company achieved a revenue of 271.04 million yuan, representing a year-on-year increase of 12.59%, while the net profit attributable to shareholders reached 171.18 million yuan, up 172.28% [1]. - The first quarter of 2025 saw a revenue of 61.79 million yuan, a decline of 12.11% year-on-year, with net profits of 10.90 million yuan and 9.20 million yuan before and after deducting non-recurring gains, respectively [1][2]. Business Segmentation - The IVD business is primarily operated by the wholly-owned subsidiary Shanghai Jiemen Biotechnology Co., Ltd., while the oral tissue repair and regeneration materials business is managed by the controlling subsidiary Shaanxi Ruisheng Biotechnology Co., Ltd. [2]. - Key performance indicators for these subsidiaries include revenue, operating costs, net profit, gross margin, and sales expense ratio, with specific figures provided for comparison over two years [3][5]. Asset Restructuring Impact - The company undertook significant asset restructuring, including the sale of a 30% stake in Cayman Pharma and the divestiture of a loss-making subsidiary, Yangling Jinhai, which improved financial metrics and operational efficiency [10][12]. - The sale of Cayman Pharma generated over 100 million yuan in investment returns, enhancing the company's liquidity and financial strength [8][10]. - The divestiture of Yangling Jinhai, which had been in a state of long-term losses, allowed the company to report a net profit of 10.90 million yuan in Q1 2025, marking a turnaround from previous losses [9][10]. Acquisition of Ruisheng Biotechnology - The company acquired a 55% stake in Shaanxi Ruisheng Biotechnology Co., Ltd. in October 2024, which contributed significantly to the net profit, amounting to 20.99 million yuan for the reporting period [13][25]. - Ruisheng's projected revenues for 2024 and 2025 are 270.04 million yuan and 320.00 million yuan, respectively, with gross margins of 90.07% and 87.63% [13][25]. Market Trends and Competitive Landscape - The medical device market is expected to grow significantly, driven by an aging population and increasing healthcare demands, with the global market projected to reach 75.38 billion USD by 2028 [17][20]. - The oral repair materials market is also expanding, with a compound annual growth rate of 30.1% from 2016 to 2019, and expected to maintain a growth rate of 15-20% through 2025 [19][20]. Sales and Revenue Dynamics - Despite a competitive market leading to price reductions, Ruisheng's proactive cost control measures resulted in a net profit of 139.25 million yuan in 2024, despite revenues falling short of projections [24][25]. - The company is focusing on maintaining market share amidst increasing competition, with strategies to optimize its distributor network and enhance operational efficiency [27][30].

关于对上海海利生物技术股份有限公司 2024年年度报告的信息披露监管 问询函回复的专项核查意见 中兴华会计师事务所(特殊普通合伙) ZHONGXINGHUA CERTIFIED PUBLIC ACCOUNTANTS LLP 地址：北京市丰台区丽泽路 20 号丽泽 SOHO Ｂ座 20 层 邮编：100073 电话：(010) 51423818 传真：(010) 51423816 中 兴 华 会 计 师 事 务 所 （ 特 殊 普 通 合 伙 ） Z H O N G X I N G H U A C E R T I F I E D P U B L I C A C C O U N T A N T S L L P 地 址 （ l o c a t i o n ） ： 北 京 市 丰 台 区 丽 泽 路 2 0 号 丽 泽 S O H O B 座 2 0 层 2 0 / F, To w e r B,L i z e SO H O , 2 0 Li z e Ro a d , F e n g t a i Distri c t ,B e i j i n g PR Ch i n a 电 话 （ t e l ） ： 0 1 0 - ...

证券代码：603718 证券简称：海利生物 公告编号：2025-032 上海海利生物技术股份有限公司 关于对上海证券交易所《关于上海海利生物技术股份 有限公司 2024 年年度报告的信息披露监管问询函》的 回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年 5 月 28 日，上海海利生物技术股份有限公司（以下简称"公司""上 市公司"或"海利生物"）收到上海证券交易所上市公司管理一部下发的《关于 上海海利生物技术股份有限公司 2024 年年度报告的信息披露监管问询函》（上证 公函【2025】0068 号）（以下简称"问询函"）。根据《问询函》的要求，公司 会同中兴华会计师事务所（特殊普通合伙）年审会计师对《问询函》所列事项逐 一复核落实，现就《问询函》所列事项逐项回复并说明如下。 本回复的字体代表以下含义： | 字体 | 含义 | | --- | --- | | 黑体（加粗） | 问询函所列问题 | | 宋体 | 对问询函所列问题的回复 | 本问询函回复中，若出现总数与各分项数值之和尾数不符的情况，均 ...

Summary of Key Points Core Viewpoint - The announcement details the results of the share reduction plan by the company's director and general manager, Han Benyi, indicating that he did not execute any share reductions during the specified period [1][2][3]. Shareholding Information - Before the reduction plan, Han Benyi held 3,000,000 shares, representing 0.4560% of the company's total share capital [1]. - Following the completion of a stock repurchase and cancellation plan, his shareholding decreased to 2,730,000 shares, which is 0.4164% of the adjusted total share capital of 655,662,200 shares [2]. Reduction Plan Implementation - The reduction plan was announced on February 20, 2025, with a proposed reduction of up to 750,000 shares, or 0.1140% of the total share capital, scheduled from March 14, 2025, to June 13, 2025 [1][2]. - As of the announcement date, Han Benyi did not reduce any shares, resulting in a total reduction of 0 shares and a remaining shareholding of 2,730,000 shares [2][3].

Summary of Key Points - The core viewpoint of the article is that Han Benyi, the director and general manager of Shanghai Haili Biotechnology Co., Ltd., did not execute his planned share reduction by the deadline, resulting in no shares being sold [1]. Group 1: Shareholding Situation Before Reduction - Before the planned reduction, Han Benyi held 3 million shares, accounting for 0.4560% of the company's original total share capital [2]. - Following the company's repurchase and cancellation of restricted shares on April 15, 2025, the total share capital changed to 655,662,200 shares, and Han Benyi's holdings were reduced to 2.73 million shares, representing 0.4164% of the total share capital [2]. Group 2: Details of the Reduction Plan - On February 20, 2025, the company announced Han Benyi's share reduction plan, which was set to occur from March 14, 2025, to June 13, 2025, allowing for a maximum reduction of 750,000 shares, or 0.1140% of the total share capital, and not exceeding 25% of his holdings [3]. - Due to the repurchase of restricted shares, Han Benyi's available shares for reduction were adjusted to a maximum of 682,500 shares [3]. Group 3: Results of the Reduction Implementation - As of June 14, 2025, the announcement date, Han Benyi did not reduce any shares, with a total reduction of 0 shares and a reduction price range of 0 - 0 CNY/share, resulting in a total amount of 0 CNY [4]. - The actual reduction situation aligned with the previously disclosed reduction plan, and the reduction period expired without any shares being sold, nor was the reduction plan terminated early [4].

本次减持前，上海海利生物技术股份有限公司（以下简称"公司"）董事兼 总经理韩本毅先生原持有公司股份 3,000,000 股，占公司原总股本的 0.4560%。 证券代码：603718 证券简称：海利生物 公告编号：2025-031 上海海利生物技术股份有限公司 董事兼总经理集中竞价减持股份计划期满 暨未减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示： 董事兼总经理持股的基本情况 | 股东名称 | 韩本毅 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | √是 | □否 | | | 其他：无 | | | | 持股数量 | 2,730,000股 | | | | 持股比例 | 0.4164% | | | | 当前持股股份来源 | 股权激励取得：2,730,000股 | | | (一)大股东及董监高因以下事项披露减 ...

Core Viewpoint - In 2024, Haili Biological (603718) underwent a significant strategic transformation by divesting long-term loss-making assets and acquiring the dental restoration materials company Ruisheng Biological, successfully shifting its focus to the human health sector. This transformation is reflected in a 172% year-on-year increase in net profit for 2024 and a turnaround to profitability in Q1 2025 with a net profit of 10.9 million yuan, a 393.11% increase year-on-year [1][2]. Group 1: Business Transformation - Haili Biological, originally established as a veterinary biological pharmaceutical factory, expanded into the human health sector in 2018 by acquiring IVD company Jiemen Biological, creating two main business segments: veterinary and IVD [2]. - The veterinary business faced continuous development pressure, leading to stagnant revenue since its IPO in 2015, which did not exceed 350 million yuan [2]. - In 2024, the company strategically adjusted its business layout by divesting loss-making veterinary assets and acquiring a 55% stake in Ruisheng Biological, focusing on high-tech dental restoration materials [2]. Group 2: Market Opportunity - Ruisheng Biological operates in a rapidly expanding market for dental implant restoration materials, benefiting from explosive demand and structural opportunities in China's dental healthcare market [3]. - Following the implementation of centralized procurement for dental implants in April 2023, the cost of a single dental implant dropped from tens of thousands to 4,000-6,000 yuan, stimulating demand [3]. - The dental implant market in China grew from approximately 27 billion yuan in 2022 to 38 billion yuan in 2023, with a projected growth to over 50 billion yuan in 2024 and 80 billion yuan by 2026 [3][4]. Group 3: Competitive Position - Ruisheng Biological has established a strong position in the domestic dental restoration materials market, with a market share that continues to rise and is accelerating the replacement of imported brands [5]. - The company’s bone repair products, made from bovine bone, and its collagen membranes have shown effective results in clinical applications, with a significant increase in sales volume [6]. - In 2023, Ruisheng Biological's bone powder sales grew by 138%, and in 2024, it is expected to continue growing by 61%, leading the market among domestic brands [6]. Group 4: Future Growth Potential - Ruisheng Biological is set to double its production capacity for bone powder from 800,000 bottles per year to 2 million bottles per year by 2025, with a 15% reduction in unit costs [6][7]. - The company is also expanding its collagen membrane production capacity and has achieved competitive pricing, winning bids in 95% of provinces under centralized procurement [7]. - Ruisheng Biological has committed to achieving a cumulative net profit of no less than 414 million yuan from 2024 to 2026, with 138 million yuan expected in 2024, indicating a feasible path to meet its performance commitments [7].

Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

证券代码：603718 证券简称：海利生物 公告编号：2025-030 上海海利生物技术股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次会议是否有否决议案：无 重要内容提示： 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 15 日 (二)股东大会召开的地点：上海市黄浦区淮海中路 138 号 805 室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 296 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 270,982,347 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 41.3295 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次年度股东大会由公司董事会召集，董事长张海明先生主持，采取现场加 网络投票方式召开并表决；会议的召集和召开符合《公司法》、《公司章程》和 ...

上海市通力律师事务所 关于上海海利生物技术股份有限公司 2024 年年度股东大会的法律意见书 致: 上海海利生物技术股份有限公司 在此基础上, 本所律师出具法律意见如下: 24SH7201004/ZYZ/kw/cm/D5 上海市通力律师事务所(以下简称"本所")接受上海海利生物技术股份有限公司(以下 简称"公司")的委托, 指派本所蔡丛丛律师、陈理民律师(以下简称"本所律师")根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和 规范性文件(以下统称"法律法规")及《上海海利生物技术股份有限公司章程》(以下简称 "公司章程")的规定就公司 2024 年年度股东大会(以下简称"本次股东大会")相关事宜 出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有 签署、盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和 有效的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东大会召集和召开的程序、 ...